CLINICAL TRIALS AND OBSERVATIONS A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
نویسندگان
چکیده
1Veridex, La Jolla, CA; 2H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa; 3Centocor R&D, Malvern, PA; 4Greenebaum Cancer Center, University of Maryland, Baltimore; 5Weill Medical College, Cornell University, New York, NY; 6Stanford Cancer Center, CA; 7Blood and Bone Marrow Transplant Group of Georgia, Atlanta; 8Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; 9Service d’Hematologie Clinique, Centre Hospitalier Universitaire (CHU) Hotel Dieu, Nantes, France; 10Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands; 11Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA; 12Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium; and 13Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia
1From the Service d’Hématologie, Hôtel Dieu, Nantes, France; 2H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa; 3Service des Maladies du Sang, Hôpital du Haut Leveque, Pessac, France; 4Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands; 5Service des Maladies du Sang, Hôpital Edouard Herriot, Lyon, France; 6Service d’Hémat...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
1H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; 2Greenebaum Cancer Center, University of Maryland, Baltimore; 3Division of Hematology, Stanford Cancer Center, CA; 4Weill Medical College, Cornell University, New York, NY; 5James P. Wilmot Cancer Center, University of Rochester, NY; 6Mayo Clinic, Rochester, MN; 7Blood and Marrow Transplant Group of Ge...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
1Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD; 2Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN; 3Department of Hematology/Oncology, New York Presbyterian Hospital, Cornell Medical Center, New York; 4Bone Marrow Transplant Group of Georgia, Atlanta; 5Investigational Drug Branch, Cancer Therapy Evaluation Program, National ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
This multicenter phase 2 study evaluated the use of tipifarnib (R115777) in patients with poor-risk myelodysplastic syndrome (MDS; French-American-British classification). Patients (n 82) received tipifarnib 300 mg orally twice daily for the first 21 days of each 28-day cycle. Twenty-six patients (32%) responded to tipifarnib: 12 (15%) complete responses (CRs) and 14 (17%) hematologic improveme...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
Patients with multiple myeloma (MM) with mutated RAS are less likely to respond to chemotherapy and have a shortened survival. Therefore, targeting RAS farnesylation may be a novel approach to treatment of MM. We evaluated the activity and tolerability of the farnesyltransferase (FTase) inhibitor tipifarnib (Zarnestra) in a phase 2 trial as well as its ability to inhibit protein farnesylation a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2008